Production and radiochemistry of antimony-120m: Efforts toward Auger electron therapy with (119)Sb

Targeted Meitner-Auger Therapy (TMAT) has potential for personalized treatment thanks to its subcellular dosimetric selectivity, which is distinct from the dosimetry of β(-) and α particle emission based Targeted Radionuclide Therapy (TRT). To date, most clinical and preclinical TMAT studies have used commercially available radionuclides. These studies showed promising results despite using radionuclides with theoretically suboptimal photon to electron ratios, decay kinetics, and electron emission spectra. Studies using radionuclides whose decay characteristics are considered more optimal are therefore important for evaluation of the full potential of Meitner-Auger therapy; (119)Sb is among the best such candidates. In the present work, we develop radiochemical purification of (120)Sb from irradiated natural tin targets for TMAT studies with (119)Sb.